Skip to main content
Top
Published in: Endocrine 2/2014

01-11-2014 | Original Article

Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms

Authors: M. Procopio, M. Barale, S. Bertaina, S. Sigrist, R. Mazzetti, M. Loiacono, G. Mengozzi, E. Ghigo, M. Maccario

Published in: Endocrine | Issue 2/2014

Login to get access

Abstract

Cardiometabolic disorders have been associated with primary hyperparathyroidism (PHPT), while the relationship of cardiovascular risk score (CRS) and metabolic syndrome (MS) with different clinical presentation of PHPT remains undefined. Our aim was to evaluate CRS, MS and its components in PHPT looking for their correlation to different clinical forms. In 68 consecutive PHPT patients and 68 matched controls, CRS, MS and its components were assessed to perform an observational case–control study at an ambulatory referral center for Bone Metabolism Diseases. Patients were stratified in symptomatic and asymptomatic PHPT; these latter were divided in high-risk and low-risk subgroups for end-organ damage. An increased proportion of PHPT patients had intermediate-high CRS and MS (mean, 95 % Confidence Interval (CI) 51.5 %, 39.6–63.3 and 20.6 %, 11.0–30.2, respectively, p < 0.02 vs. controls). Intermediate-high CRS was prevalent both in symptomatic and low-risk asymptomatic PHPT while MS resulted prevalent in low-risk asymptomatic but not in symptomatic PHPT. Type 2 DM, IFG, mixed dyslipidemia, hypertriglyceridemia, HDL-hypocholesterolemia, and LDL-hypercholesterolemia predominated in low-risk asymptomatic, while only LDL-hypercholesterolemia prevailed also in symptomatic PHPT. In patients and controls without cardiometabolic risk factors, HOMA-IR index was significantly increased in PHPT vs. controls (p < 0.03) and associated to total calcium (R = 0.73; p < 0.001). By multivariate analysis low-risk asymptomatic PHPT predicted MS after adjusting for age, sex, and BMI. Our data show an increased frequency of intermediate-high CRS both in symptomatic and low-risk asymptomatic PHPT while MS prevails in low-risk asymptomatic PHPT, supporting the potential for cardiovascular morbidity and mortality also in this form.
Literature
1.
go back to reference S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 351–365 (2009)PubMedCrossRef S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 351–365 (2009)PubMedCrossRef
2.
go back to reference I.L. Nilsson, L. Yin, E. Lundgren, J. Rastad, A. Ekbom, Clinical presentation of primary hyperparathyroidism in Europe–nationwide cohort analysis on mortality from nonmalignant causes. J. Bone Miner. Res. 17(Suppl 2), N68–N74 (2002)PubMed I.L. Nilsson, L. Yin, E. Lundgren, J. Rastad, A. Ekbom, Clinical presentation of primary hyperparathyroidism in Europe–nationwide cohort analysis on mortality from nonmalignant causes. J. Bone Miner. Res. 17(Suppl 2), N68–N74 (2002)PubMed
3.
go back to reference N. Yu, P.T. Donnan, R.W. Flynn, M.J. Murphy, D. Smith, A. Rudman, G.P. Leese, Increased mortality and morbidity in mild primary hyperparathyroid patients. The parathyroid epidemiology and audit research study (PEARS). Clin. Endocrinol. 73, 30–34 (2010) N. Yu, P.T. Donnan, R.W. Flynn, M.J. Murphy, D. Smith, A. Rudman, G.P. Leese, Increased mortality and morbidity in mild primary hyperparathyroid patients. The parathyroid epidemiology and audit research study (PEARS). Clin. Endocrinol. 73, 30–34 (2010)
4.
go back to reference E. Osto, F. Fallo, M.R. Pelizzo, A. Maddalozzo, N. Sorgato, F. Corbetti, R. Montisci, G. Famoso, R. Bellu, T.F. Lüscher, S. Iliceto, F. Tona, Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)PubMedCrossRef E. Osto, F. Fallo, M.R. Pelizzo, A. Maddalozzo, N. Sorgato, F. Corbetti, R. Montisci, G. Famoso, R. Bellu, T.F. Lüscher, S. Iliceto, F. Tona, Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)PubMedCrossRef
5.
go back to reference M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008)PubMedCrossRef M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008)PubMedCrossRef
6.
go back to reference F. Tassone, M. Procopio, L. Gianotti, G. Visconti, A. Pia, M. Terzolo, G. Borretta, Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet. Med. 26, 968–973 (2009)PubMedCrossRef F. Tassone, M. Procopio, L. Gianotti, G. Visconti, A. Pia, M. Terzolo, G. Borretta, Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet. Med. 26, 968–973 (2009)PubMedCrossRef
7.
go back to reference E. Hagstrom, E. Lundgren, H. Lithell, L. Berglund, S. Ljunghall, P. Hellman, J. Rastad, Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin. Endocrinol. 56, 253–260 (2002)CrossRef E. Hagstrom, E. Lundgren, H. Lithell, L. Berglund, S. Ljunghall, P. Hellman, J. Rastad, Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin. Endocrinol. 56, 253–260 (2002)CrossRef
8.
go back to reference A. Bergenfelz, A. Bladström, M. Their, E. Nordenström, S. Valdemarsson, J. Westerdahl, Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J. Surg. 31, 1393–1400 (2007)PubMedCrossRef A. Bergenfelz, A. Bladström, M. Their, E. Nordenström, S. Valdemarsson, J. Westerdahl, Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J. Surg. 31, 1393–1400 (2007)PubMedCrossRef
9.
go back to reference M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)PubMedCrossRef M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)PubMedCrossRef
10.
go back to reference E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, E. D’ Erasmo, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)PubMedCrossRef E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, E. D’ Erasmo, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)PubMedCrossRef
11.
go back to reference R. Luboshitzky, Y. Chertok-Schaham, I. Lavi, A. Ishay, Cardiovascular risk factors in primary hyperparathyroidism. J. Endocrinol. Invest. 32, 317–321 (2009)PubMedCrossRef R. Luboshitzky, Y. Chertok-Schaham, I. Lavi, A. Ishay, Cardiovascular risk factors in primary hyperparathyroidism. J. Endocrinol. Invest. 32, 317–321 (2009)PubMedCrossRef
12.
go back to reference D. Han, S. Trooskin, X. Wang, Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.3275/7861 D. Han, S. Trooskin, X. Wang, Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.​3275/​7861
13.
go back to reference E. Hagström, P. Hellman, T.E., E. Ingelsson, L. Berglund, J. Sundström, H. Melhus, C. Held, L. Lind, K. Michaëlsson, J. Arnlöv. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 119, 2765–2771 (2009) E. Hagström, P. Hellman, T.E., E. Ingelsson, L. Berglund, J. Sundström, H. Melhus, C. Held, L. Lind, K. Michaëlsson, J. Arnlöv. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 119, 2765–2771 (2009)
14.
go back to reference J.L. Anderson, R.C. Vanwoerkom, B.D. Horne, T.L. Bair, H.T. May, D.L. Lappé, J.B. Muhlestein, Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am. Heart J. 162, 331–339 (2011)PubMedCrossRef J.L. Anderson, R.C. Vanwoerkom, B.D. Horne, T.L. Bair, H.T. May, D.L. Lappé, J.B. Muhlestein, Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am. Heart J. 162, 331–339 (2011)PubMedCrossRef
16.
go back to reference J.P. Bilezikian, A.A. Khan, J.T. Potts Jr, Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009)PubMedCrossRefPubMedCentral J.P. Bilezikian, A.A. Khan, J.T. Potts Jr, Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009)PubMedCrossRefPubMedCentral
17.
go back to reference F. Tassone, L. Gianotti, C. Baffoni, F. Cesario, G. Magro, M. Pellegrino, I. Emmolo, M. Maccario, G. Borretta, Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.3275/8192 PubMed F. Tassone, L. Gianotti, C. Baffoni, F. Cesario, G. Magro, M. Pellegrino, I. Emmolo, M. Maccario, G. Borretta, Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.​3275/​8192 PubMed
18.
go back to reference Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002)
19.
go back to reference D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef
21.
go back to reference G. Mansia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Struijker Boudier, A. Zanchetti, European Society of Hypertension; European Society of Cardiology. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Blood. Press 16, 135–232 (2007) G. Mansia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Struijker Boudier, A. Zanchetti, European Society of Hypertension; European Society of Cardiology. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Blood. Press 16, 135–232 (2007)
22.
go back to reference J.B. Meigs, P.W.F. Wilson, D.M. Nathan, R.B. D’Agostino Sr, K. Williams, S.M. Haffner, Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 52, 2160–2167 (2003)PubMedCrossRef J.B. Meigs, P.W.F. Wilson, D.M. Nathan, R.B. D’Agostino Sr, K. Williams, S.M. Haffner, Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 52, 2160–2167 (2003)PubMedCrossRef
23.
go back to reference T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)PubMedCrossRef T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)PubMedCrossRef
24.
go back to reference D.A. De Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012). doi:10.1002/jcla.21541 PubMedCrossRef D.A. De Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012). doi:10.​1002/​jcla.​21541 PubMedCrossRef
25.
go back to reference P. Luigi, F.M. Chiara, Z. Laura, M. Cristiano, C. Giuseppina, C. Luciano, P. Giuseppe, C. Sabrina, S. Susanna, C. Antonio, C. Giuseppe, T. Giorgio, L. de Claudio, Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int. J. Endocrinol. (2012). doi:10.1155/2012/408295 PubMedPubMedCentral P. Luigi, F.M. Chiara, Z. Laura, M. Cristiano, C. Giuseppina, C. Luciano, P. Giuseppe, C. Sabrina, S. Susanna, C. Antonio, C. Giuseppe, T. Giorgio, L. de Claudio, Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int. J. Endocrinol. (2012). doi:10.​1155/​2012/​408295 PubMedPubMedCentral
26.
go back to reference E. Hagstrom, E. Lundgren, J. Rastad, P. Hellman, Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur. J. Endocrinol. 155, 33–39 (2006)PubMedCrossRef E. Hagstrom, E. Lundgren, J. Rastad, P. Hellman, Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur. J. Endocrinol. 155, 33–39 (2006)PubMedCrossRef
27.
go back to reference K.M. Tordjman, M. Yaron, E. Izkhakov, E. Osher, G. Shenkerman, Y. Marcus-Perlman, N. Stern, Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur. J. Endocrinol. 162, 925–933 (2010)PubMedCrossRef K.M. Tordjman, M. Yaron, E. Izkhakov, E. Osher, G. Shenkerman, Y. Marcus-Perlman, N. Stern, Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur. J. Endocrinol. 162, 925–933 (2010)PubMedCrossRef
29.
go back to reference J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenström, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)PubMedCrossRef J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenström, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)PubMedCrossRef
30.
go back to reference A.A. Khaleeli, J.N. Johnson, W.H. Taylor, Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab. Res. Rev. 23, 43–48 (2007)PubMedCrossRef A.A. Khaleeli, J.N. Johnson, W.H. Taylor, Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab. Res. Rev. 23, 43–48 (2007)PubMedCrossRef
31.
go back to reference M.R. Rubin, S.J. Silverberg, Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 42, 231–233 (2012)PubMedCrossRef M.R. Rubin, S.J. Silverberg, Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 42, 231–233 (2012)PubMedCrossRef
32.
go back to reference A. Kautzky-Willer, G. Pacini, B. Niederle, G. Schernthaner, R. Prager, Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin. Endocrinol. 37, 147–155 (1992)CrossRef A. Kautzky-Willer, G. Pacini, B. Niederle, G. Schernthaner, R. Prager, Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin. Endocrinol. 37, 147–155 (1992)CrossRef
33.
go back to reference S. Kumar, A.O. Olukoga, C. Gordon, E.B. Mawer, M. France, J.P. Hosker, M. Davies, A.J. Boulton, Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin. Endocrinol. 40, 47–53 (1994)CrossRef S. Kumar, A.O. Olukoga, C. Gordon, E.B. Mawer, M. France, J.P. Hosker, M. Davies, A.J. Boulton, Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin. Endocrinol. 40, 47–53 (1994)CrossRef
34.
go back to reference F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba, F. Cesario, G. Magro, G. Borretta, Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine (2013). doi:10.1007/s12020-013-0059-z PubMed F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba, F. Cesario, G. Magro, G. Borretta, Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine (2013). doi:10.​1007/​s12020-013-0059-z PubMed
35.
go back to reference I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419–422 (2012)PubMedCrossRef I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419–422 (2012)PubMedCrossRef
36.
go back to reference T. Yamaguchi, I. Kanazawa, S. Takaoka, T. Sugimoto, Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. Metabolism 60, 1334–1339 (2011)PubMedCrossRef T. Yamaguchi, I. Kanazawa, S. Takaoka, T. Sugimoto, Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. Metabolism 60, 1334–1339 (2011)PubMedCrossRef
37.
go back to reference P.J. Buizert, N.M. van Schoor, S. Simsek, P. Lips, A.C. Heijboer, M. den Heijer, D.J. Deeg, E.M. Eekhoff, PTH: a new target in arteriosclerosis? J Clin Endocrinol Metab (2013). doi:10.1210/jc.2013-1621 PubMed P.J. Buizert, N.M. van Schoor, S. Simsek, P. Lips, A.C. Heijboer, M. den Heijer, D.J. Deeg, E.M. Eekhoff, PTH: a new target in arteriosclerosis? J Clin Endocrinol Metab (2013). doi:10.​1210/​jc.​2013-1621 PubMed
38.
go back to reference T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jørgensen, B.H. Thuesen, M. Fenger, A. Linneberg, Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 43, 618–625 (2013)PubMedCrossRef T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jørgensen, B.H. Thuesen, M. Fenger, A. Linneberg, Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 43, 618–625 (2013)PubMedCrossRef
Metadata
Title
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms
Authors
M. Procopio
M. Barale
S. Bertaina
S. Sigrist
R. Mazzetti
M. Loiacono
G. Mengozzi
E. Ghigo
M. Maccario
Publication date
01-11-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0091-z

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.